BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: NAD(P) dependent steroid dehydrogenase-like (NSDHL); K-Ras (KRAS)

...expressing an oncogenic mutation of human KRAS , NSDHL knockout decreased proliferation compared with normal NSDHL...
...decreased tumor growth compared with normal NSDHL expression. Next steps could include testing inhibition of NSDHL...
...expression. Next steps could include testing inhibition of NSDHL in models of other cancers. TARGET/MARKER/PATHWAY: NAD(P) dependent steroid dehydrogenase-like (NSDHL)...
Items per page:
1 - 1 of 1